...
search icon
xgn-img

Exagen Inc, Common Stock

XGN

NMQ

$3.78

-$0.06

(-1.56%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$66.67M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
46.98K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.41
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.3 L
$6.22 H
$3.78

About Exagen Inc, Common Stock

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameXGNSectorS&P500
1-Week Return-11.48%0.54%0.54%
1-Month Return-5.74%3.28%1.66%
3-Month Return-10%3.01%3.83%
6-Month Return25.58%-4.69%9.77%
1-Year Return79.15%1.41%23.47%
3-Year Return-54.18%15.72%42.73%
5-Year Return-79.43%42.38%82.01%
10-Year Return-77.91%103.91%190.88%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue40.39M41.98M48.30M45.56M52.55M[{"date":"2019-12-31","value":76.86,"profit":true},{"date":"2020-12-31","value":79.88,"profit":true},{"date":"2021-12-31","value":91.91,"profit":true},{"date":"2022-12-31","value":86.71,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue18.81M16.56M20.59M24.21M23.09M[{"date":"2019-12-31","value":77.67,"profit":true},{"date":"2020-12-31","value":68.39,"profit":true},{"date":"2021-12-31","value":85.03,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":95.37,"profit":true}]
Gross Profit21.58M25.42M27.71M21.35M29.46M[{"date":"2019-12-31","value":73.26,"profit":true},{"date":"2020-12-31","value":86.28,"profit":true},{"date":"2021-12-31","value":94.08,"profit":true},{"date":"2022-12-31","value":72.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin53.43%60.55%57.37%46.86%56.06%[{"date":"2019-12-31","value":88.24,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":94.75,"profit":true},{"date":"2022-12-31","value":77.38,"profit":true},{"date":"2023-12-31","value":92.58,"profit":true}]
Operating Expenses30.88M40.60M51.78M61.89M52.29M[{"date":"2019-12-31","value":49.89,"profit":true},{"date":"2020-12-31","value":65.6,"profit":true},{"date":"2021-12-31","value":83.66,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.49,"profit":true}]
Operating Income(9.30M)(15.19M)(24.07M)(40.55M)(22.84M)[{"date":"2019-12-31","value":-929900000,"profit":false},{"date":"2020-12-31","value":-1518500000,"profit":false},{"date":"2021-12-31","value":-2406700000,"profit":false},{"date":"2022-12-31","value":-4054500000,"profit":false},{"date":"2023-12-31","value":-2283700000,"profit":false}]
Total Non-Operating Income/Expense(6.21M)(4.15M)(5.23M)(3.24M)(2.38M)[{"date":"2019-12-31","value":-620500000,"profit":false},{"date":"2020-12-31","value":-414600000,"profit":false},{"date":"2021-12-31","value":-523400000,"profit":false},{"date":"2022-12-31","value":-323600000,"profit":false},{"date":"2023-12-31","value":-238400000,"profit":false}]
Pre-Tax Income(12.01M)(16.77M)(26.68M)(47.67M)(23.66M)[{"date":"2019-12-31","value":-1201300000,"profit":false},{"date":"2020-12-31","value":-1676600000,"profit":false},{"date":"2021-12-31","value":-2667600000,"profit":false},{"date":"2022-12-31","value":-4766900000,"profit":false},{"date":"2023-12-31","value":-2365600000,"profit":false}]
Income Taxes25.00K(79.00K)175.00K(282.00K)33.00K[{"date":"2019-12-31","value":14.29,"profit":true},{"date":"2020-12-31","value":-45.14,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-161.14,"profit":false},{"date":"2023-12-31","value":18.86,"profit":true}]
Income After Taxes(12.04M)(16.69M)(26.85M)(47.39M)(23.69M)[{"date":"2019-12-31","value":-1203800000,"profit":false},{"date":"2020-12-31","value":-1668700000,"profit":false},{"date":"2021-12-31","value":-2685100000,"profit":false},{"date":"2022-12-31","value":-4738700000,"profit":false},{"date":"2023-12-31","value":-2368900000,"profit":false}]
Income From Continuous Operations(12.04M)(16.69M)(26.85M)(47.39M)(32.47M)[{"date":"2019-12-31","value":-1203800000,"profit":false},{"date":"2020-12-31","value":-1668700000,"profit":false},{"date":"2021-12-31","value":-2685100000,"profit":false},{"date":"2022-12-31","value":-4738700000,"profit":false},{"date":"2023-12-31","value":-3247000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(12.04M)(16.69M)(26.85M)(47.39M)(23.69M)[{"date":"2019-12-31","value":-1203800000,"profit":false},{"date":"2020-12-31","value":-1668700000,"profit":false},{"date":"2021-12-31","value":-2685100000,"profit":false},{"date":"2022-12-31","value":-4738700000,"profit":false},{"date":"2023-12-31","value":-2368900000,"profit":false}]
EPS (Diluted)(4.44)(1.32)(1.70)(2.68)(1.34)[{"date":"2019-12-31","value":-444,"profit":false},{"date":"2020-12-31","value":-132,"profit":false},{"date":"2021-12-31","value":-170,"profit":false},{"date":"2022-12-31","value":-268,"profit":false},{"date":"2023-12-31","value":-134,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

XGN
Cash Ratio 2.51
Current Ratio 4.05

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

XGN
ROA (LTM) -18.42%
ROE (LTM) -83.86%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

XGN
Debt Ratio Lower is generally better. Negative is bad. 0.70
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.30

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

XGN
Trailing PE NM
Forward PE NM
P/S (TTM) 1.21
P/B 5.16
Price/FCF NM
EV/R 1.22
EV/Ebitda NM

FAQs

What is Exagen Inc share price today?

Exagen Inc (XGN) share price today is $3.78

Can Indians buy Exagen Inc shares?

Yes, Indians can buy shares of Exagen Inc (XGN) on Vested. To buy Exagen Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in XGN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Exagen Inc be purchased?

Yes, you can purchase fractional shares of Exagen Inc (XGN) via the Vested app. You can start investing in Exagen Inc (XGN) with a minimum investment of $1.

How to invest in Exagen Inc shares from India?

You can invest in shares of Exagen Inc (XGN) via Vested in three simple steps:

  • Click on Sign Up or Invest in XGN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Exagen Inc shares
What is Exagen Inc 52-week high and low stock price?

The 52-week high price of Exagen Inc (XGN) is $6.22. The 52-week low price of Exagen Inc (XGN) is $1.3.

What is Exagen Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Exagen Inc (XGN) is 5.16

What is the Market Cap of Exagen Inc?

The market capitalization of Exagen Inc (XGN) is $66.67M

What is Exagen Inc’s stock symbol?

The stock symbol (or ticker) of Exagen Inc is XGN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top